Branched rolling circle amplification method for measuring serum circulating micro<scp>RNA</scp> levels for early breast cancer detection

Fan, Tingting; Mao, Yu; Sun, Qiao; Liu, Feng; Lin, Jin‐Shun; Liu, Yajie; Cui, Junwei; Jiang, Yuyang

doi:10.1111/cas.13725

Cited by 47 publications

(38 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are various studies that mention hsa-miR-155; a search of PubMed (accessed January 10, 2020) found 191 reports for 'miR-155 AND breast cancer'; 22 reports for 'miR-155 AND triple negative breast cancer'; and 3 reports for 'circulating miR-155 AND triple negative breast cancer'. Together, these studies demonstrate the well-acknowledged role of hsa-miR-155 in the early detection, tumor initiation, and cancer development and progression of BC (81,87,119).…”

Section: Pd-l1 and Circulating Mirnas In Tnbc Pd-l1 Is A Cell Membramentioning

confidence: 56%

Circulating microRNAs and their role in the immune response in triple‑negative breast cancer (Review)

2020

View full text Add to dashboard Cite

Breast cancer (BC) is the most common type of cancer in women worldwide, and despite advances in treatments, its incidence and mortality are increasing. Therefore, it is necessary to develop new, non-invasive tests that provide more accurate diagnosis and prognosis in a timely manner. A promising approach is measuring the presence of biomarkers to detect tumors at various stages and determine their specific characteristics, thus allowing for more personalized treatment. MicroRNAs (miRNAs) serve a role in gene expression, primarily by interacting with messenger RNAs, and may be potential biomarkers for detecting cancer. They are detectable in tissues and blood, including plasma and/or serum, are stable and often tumor specific. Also, different miRNAs are associated with specific BC molecular subtypes. Triple-negative BC (TNBC) is a type of BC in which the primary targets for hormonal therapy are absent. It is an aggressive phenotype, which frequently metastasizes and is associated with an unfavorable prognosis. The present review focuses on circulating miRNAs in patients with TNBC, with an emphasis on their interaction with the immune response checkpoint genes PD-1, PD-L1 and CTLA4. Modulation and response of the immune system are of interest in cancer treatment due to the success of immunotherapy in the treatment of various neoplasms. Based on the findings of this literature review and the in silico analysis performed as part of this review, it is concluded that circulating hsa-miR-195 and hsa-miR-155 in TNBC interact with checkpoint genes involved in the immune response. Further analysis of the expression of these circulating miRNAs and their association with prognosis in patients with TNBC treated with immunotherapy should be assessed to evaluate their possible use as non-invasive predictive biomarkers. In addition, functional studies to analyze biologically relevant targets in the development and prognosis of TNBC, which could be therapeutic targets, are also recommended. Contents 1. Introduction 2. miRNAs as biomarkers in BC 3. Circulating miRNAs in BC 4. Checkpoints and miRNAs in TNBC 5. Conclusions

show abstract

Section: Pd-l1 and Circulating Mirnas In Tnbc Pd-l1 Is A Cell Membramentioning

confidence: 56%

Circulating microRNAs and their role in the immune response in triple‑negative breast cancer (Review)

2020

View full text Add to dashboard Cite

show abstract

“…Serum microRNAs are little in content and short in length. [43][44][45][46] In addition, microRNAs are pochissimo in serum and below the lower limit of the spectrophotometer. 41 In this study, a special microRNA adsorption column was used for RNA extraction.…”

Section: Discussionmentioning

confidence: 99%

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

Yin

Yang

et al. 2019

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cervical cancer is the third leading cause of female death in the world. Serum microRNAs (miRNAs) are currently considered to be valuable as noninvasive cancer biomarkers, but their role in the prognosis of cervical cancer has not been elucidated. We aimed to find serum miRNAs that can be used as prognostic factors for cervical cancer. A traumatic pathological biopsy is the only reliable method for determining the severity of cervical cancer currently. Thus, noninvasive diagnostic markers are needed. The serological expression of candidate miRNAs were measured in 90 participants, including 60 patients with cervical cancer and 50 patients with cervical intraepithelial neoplasia. Two patients with cervical cancer were excluded from the study because of lack of data. miRNAs were evaluated by quantitative reverse transcription polymerase chain reaction. miR‐143/−4636 appeared specific for cervical cancer compared with cervical intraepithelial neoplasia (P < .001). The classification performance of validated miRNAs for cervical cancer [Area under the receiver operating characteristic curve (AUC) = 0.942] was better than that reached by squamous cell carcinoma antigen (SCC‐Ag; AUC = 0.727). Poor‐differentiation group has lower miR‐143/−4636 levels in serum (P < .05). miR‐4636 level was correlated gross tumor volume and the depth of invasion (P < .0001). In our study, we found a combination of miR‐143 and miR‐4636 that is independently and strongly associated with cervical cancer prognosis and can be used as a clinically prognostic factor.

show abstract

“…The same results were observed in serum of patients with LumA compared to healthy controls. Finally, the measurement of the level of circulating miRNAs by BRCA assay, especially the combination of miR-16, miR-21, miR-155, and miR-195, could be used to detect LumA BC [ 40 ]. Moreover, the expression of circulating miR-10b, miR-21, miR-145, miR-155, miR-195 was increased in the blood of predominantly early stage and LumA patients compared to healthy controls but only miR-195 expression was specific to the EBC cohort compared to other cancer types and healthy control.…”

Section: Specific Mirna Expressionin Early and Metastatic Stage Inmentioning

confidence: 99%

miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment

Kúdela

Samec

Koklesová

et al. 2020

IJMS

View full text Add to dashboard Cite

Breast cancer, which is the most common malignancy in women, does not form a uniform nosological unit but represents a group of malignant diseases with specific clinical, histopathological, and molecular characteristics. The increasing knowledge of the complex pathophysiological web of processes connected with breast cancercarcinogenesis allows the development of predictive and prognostic gene expressionand molecular classification systems with improved risk assessment, which could be used for individualized treatment. In our review article, we present the up-to-date knowledge about the role of miRNAs and their prognostic and predictive value in luminal A breast cancer. Indeed, an altered expression profile of miRNAs can distinguish not only between cancer and healthy samples, but they can classify specific molecular subtypes of breast cancer including HER2, Luminal A, Luminal B, and TNBC. Early identification and classification of breast cancer subtypes using miRNA expression profilescharacterize a promising approach in the field of personalized medicine. A detection of sensitive and specific biomarkers to distinguish between healthy and early breast cancer patients can be achieved by an evaluation of the different expression of several miRNAs. Consequently, miRNAs represent a potential as good diagnostic, prognostic, predictive, and therapeutic biomarkers for patients with luminal A in the early stage of BC.

show abstract

Branched rolling circle amplification method for measuring serum circulating microRNA levels for early breast cancer detection

Cited by 47 publications

References 39 publications

Circulating microRNAs and their role in the immune response in triple‑negative breast cancer (Review)

Circulating microRNAs and their role in the immune response in triple‑negative breast cancer (Review)

Peripheral blood circulating microRNA‐4636/−143 for the prognosis of cervical cancer

miRNA Expression Profiles in Luminal A Breast Cancer—Implications in Biology, Prognosis, and Prediction of Response to Hormonal Treatment

Contact Info

Product

Resources

About